anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a severe complication of cirrhosis that carries a poor prognosis. The recent Food and Drug Administration approval of terlipressin has substantial implications for managing HRS-AKI and liver allocation in the United States. Terlipressin has been available in Europe for over a decade, and several countries have adapted policy changes such as Model for End-Stage Liver Disease (MELD) score "lock" for HRS-AKI. In this article, we outline the European experience with terlipressin use and explore the question of whether terlipressin treatment for HRS-AKI should qualify for the MELD score "lock" in the United States in those who respond to therapy. Arguments for the MELD lock include protecting waitlist priority for terlipressin responders or partial responders who may miss offers due to MELD reduction in the terlipressin treatment window. Arguments against MELD lock include the fact that terlipressin may produce a durable response and improve overall survival and that equitable access to terlipressin is not guaranteed due to cost and availability. We subsequently discuss the proposed next steps for studying terlipressin implementation in the United States. A successful approach will require the involvement of all major stakeholders and the mobilization of our transplant community to spearhead research in this area.
Reduction in alveolar ridge height and width may prohibit optimal implant placement, and often compromises the esthetic and functional result. Alveolar ridge preservation has been evaluated in many studies. A variety of bone grafting materials and barrier membranes have been studied for their ability to enhance bone formation in damaged alveolar ridges, and to evaluate their bone healing and bone-forming capacity in extraction sockets. However, the newly developed resorbable collagen membrane OSSIX-Plus has not been evaluated for this purpose. This study is designed to test the ability of OSSIX-Plus (OraPharma Inc., Warminster, Pennsylvania) in promoting optimal bone healing following exodontia. We hypothesize that use of OSSIX-Plus will result in preservation of the height, width and density of the residual alveolar ridge following tooth extraction.
The medical devices of the invention comprise a portion having a porous surface for release of at least one biologically active agent therefrom. The porous surface is made of a material such as a polymer having a plurality of voids. To load the porous surface with a biologically active agent or drug, an electrophoresis method is employed. In this method, a device having a porous surface is placed into a drug solution or suspension, along with an electrode. An electric current is applied to the device and electrode. Under such a current, the drug, which has a positive or negative charge, will be loaded into the pores or voids of the porous surface.
We investigated the effects of a centrally penetrant ghrelin agonist, RQ-00538053, on colorectal motility in female rats in comparison with that in male rats. Intravenous administration of RQ-00538053 enhanced colorectal motility in female rats. However, approximately tenfold higher doses were required to induce responses in female rats similar to those in male rats. Higher doses were required even when the agonist was intrathecally administered to the lumbosacral spinal cord in female rats. The results of RT-qPCR showed that the level of ghrelin receptor expression in the lumbosacral spinal cord was lower in female rats than in male rats, suggesting that the lower expression level of the receptor may contribute, at least in part, to the sex differences in the action of RQ-00538053. The sexually dimorphic action of a ghrelin agonist will be important for future works aiming to utilize ghrelin agonists as novel drugs to improve constipation.
INTRODUCTION: Appendicitis is a common cause of acute abdomen. Although many guidelines exist to aid in the preoperative diagnosis of appendicitis in children, histology remains the definitive diagnostic method. Histological diagnosis is premised on the presence of inflammatory infiltrates beyond the mucosa and involving the submucosa and muscularis propria. Involvement of the serosa is often associated with peritonitis. Appendices with no pathology have uncommonly been reported with the clinical diagnosis of appendicitis.
OBJECTIVE: We present the pathological features of appendicitis in 32 children over two years.
METHODS: Pathology Department records of consecutive appendectomies in children were retrieved over two years. The gross descriptions were documented and histological assessment of the H&E stained slides was done. Notes were made on the appendix length, obvious gross abnormalities and perforation; histological presence of mucosal lymphoid hyperplasia and ulceration, predominant inflammatory cell type, presence of reparative changes in the submucosa, and involvement of the peritoneum. Appendectomy performed as an addition to other therapies were excluded.
RESULT: Thirty-two children had appendectomies for acute appendicitis, their ages ranged from 4 months to 17 years (median 14.5 years) and there were 12 females (37.5%) and 20 males (62.5%). Appendicitis could be grouped into simple (acute appendicitis without perforation, suppuration, or peritonitis) 11 (34.4%), complicated (acute appendicitis with perforation, gangrene, and/or suppuration) 14 (43.7%), subacute/ chronic (acute appendicitis with reparative changes or non-specific chronic inflammation) 7 (21.9%). All cases had associated mucosal lymphoid hyperplasia. No negative appendix was seen.
CONCLUSION: Appendicitis in children is often complicated before surgical intervention.
BACKGROUND: Acute otitis media (AOM) is a common childhood disease frequently caused by Streptococcus pneumoniae. Pneumococcal conjugate vaccines (PCV7, PCV10, PCV13) can reduce the risk of AOM but may also shift AOM etiology and serotype distribution. The aim of this study was to review estimates from published literature of the burden of AOM in Europe after widespread use of PCVs over the past 10 years, focusing on incidence, etiology, serotype distribution and antibiotic resistance of Streptococcus pneumoniae, and economic burden.
METHODS: This systematic review included published literature from 31 European countries, for children aged ≤5 years, published after 2011. Searches were conducted using PubMed, Embase, Google, and three disease conference websites. Risk of bias was assessed with ISPOR-AMCP-NPC, ECOBIAS or ROBIS, depending on the type of study.
RESULTS: In total, 107 relevant records were identified, which revealed wide variation in study methodology and reporting, thus limiting comparisons across outcomes. No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5-38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14-24%, depending on country), following the widespread use of PCVs over time. The last two trends imply a potential decrease in economic burden, though this was not possible to confirm with the identified cost data. There was also evidence of an increase in serotype distributions towards non-vaccine serotypes in all of the countries where non-PCV serotype data were available, as well as limited data of increased antibiotic resistance within non-vaccine serotypes.
CONCLUSIONS: Though some factors point to a reduction in AOM burden in Europe, the burden still remains high, residual burden from uncovered serotypes is present and it is difficult to provide comprehensive, accurate and up-to-date estimates of said burden from the published literature. This could be improved by standardised methodology, reporting and wider use of surveillance systems.
Hypertension is one of the most common chronic diseases and it is an important global public health problem. In cardiac rehabilitation programs, aerobic exercise, resistance exercise and a combination of aerobic and resistance exercise are recommended to reduce cardiovascular risk. Whole body vibration training has also started to be used among new applications in the cardiac rehabilitation programs. Whole body vibration training has been reported as an effective and safe approach for both healthy and cardiovascular diseased women and men. It has been shown to be beneficial in improving atherosclerosis and blood pressure in hypertensive patients. In whole body vibration training, frequencies of 20-40 Hz are generally used for hypertensive elderly patients. However, the optimal frequency in this population has not been fully determined. For these reasons, the aim of the study is to compare the acute effects of using different frequencies in whole body vibration training in hypertensive patients.

Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at three different frequencies (0, 25 and 40 Hz). Each patient will complete the training in these 3 frequencies in random order and on different days. Before and after the sessions; hemodynamic and pulmonary responses, vascular responses, heart rate variability and quadriceps femoris muscle strength will be measured. In addition, energy expenditure will be recorded during the sessions.Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes. Participants will perform whole body vibration trainings at different frequencies in a randomized order with at least one day apart.
SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 \& 7 when it will be administered biweekly on days 1 \& 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 \& 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
OBJECTIVES: This study was designed to evaluate the association of four surrogate indexes of IR with NASH in patients with obesity.
METHODS: A total of 270 patients who underwent bariatric surgery, were included in this cross-sectional study. NASH was diagnosed based on liver biopsies. Binary logistics regression analyses were performed to assess the associations of four surrogate indexes of IR (HOMA-IR, Matsuda index, TyG, and TG/HDL-C) with NASH in patients with obesity. The restricted cubic spline was used to assess the dose-response associations of surrogate indexes of IR with NASH after adjusting for confounding factors.
RESULTS: NASH was diagnosed in 136 patients, with a prevalence of 50.37%. Compared with tertile 1, the fully adjusted ORs (95% CIs) of NASH for tertile 3 were 2.711(1.113-6.608) and 0.297 (0.152-0.579) for TyG and Matsuda index. Consistently, per SD increment of TyG were still significantly associated with 64% increased risks of NASH, and per SD increment of Matsuda index were still significantly associated with 38% decreased risks of NASH. In contrast, no significant associations were found between HOMA-IR and TG/HDL-C and the risk of NASH in patients with obesity (all P > 0.05). After adjusting covariates in restricted cubic splines, the risk of NASH decreased with the increment of Matsuda Index levels (P-nonlinear = 0.442, P-overall = 0.007) and with the decrement of TyG levels (P-nonlinear = 0.004, P-overall = 0.001).
CONCLUSIONS: In patients with obesity, TyG and Matsuda index were independently related to the risk of NASH after adjustment for traditional risk factors. In addition, compared with HOMA-IR and TG/HDL-C, the Matsuda index and TyG may be more suitable for NASH prediction in patients with obesity.
Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
The invention relates to means for treatment of acute and chronic infections with viruses pathogenic to both humans and animals, which assemble at the cell membrane and are released from the cell surface by budding. The above are pathogens for infectious diseases such as AIDS, hepatitis, haemorrhagic fever, SARS, smallpox, measles, polio or flu. Said means contain inhibitors of protein folding as active ingredients, including inhibitors of cellular folding enzymes (enzymatic chaperones) and also substances which block protein folding by chemical chaperones. The following substance classes and derivatives thereof belong to the above: geldanamycin, deoxyspergualin, 4-PBA or herbimycin A. The highly organised processes of the assembly and proteolytic maturation of viral structure proteins are inhibited by said means. As a result the release and production of infectious filial viruses are interrupted.
In oral and maxillofacial surgery, surgical extraction of impacted third molars is one of the most common surgical techniques performed in the oral cavity. Conscious intravenous sedation could be administered for the patients to provide anxiolysis, sedation, and analgesia for the patient. Salivary alpha-amylase (sAA) which reflect stress-related changes in the autonomic nervous system (ANS), has been proposed as a non-invasive stress biomarker. The aim of the present study was to investigate whether salivary alpha amylase (sAA) levels could be decreased by conscious sedation in the patients undergoing impacted third molar extraction. A total of 18 male patients were recruited. All patients were administered Modified Dental Anxiety Scale (MDAS) test. Patients were divided into two groups: test group (procedures under sedation) and control group (procedures under local anesthesia). The following parameters were monitored at different study time-points: systolic blood pressure (SBP), diastolic blood pressure (DBP), oxygen saturation (SO2), and heart rate (HR). Five samples of saliva were taken from each patient: the first time patient came to clinic, the patient sat in the chair for extraction, before local anesthesia, immediately after extraction, at 4 h after extraction. The concentrations of sAA were measured and compared across the different stages of the study between two groups.
Modified T cell receptors, cells comprising the modified T cell receptors, nucleic acids encoding the modified T cell receptors, and methods for using the modified T cell receptors are contemplated. Modified T cell receptor comprising two peptide chains are disclosed herein. The two peptide chains may be the same or different, and each peptide chain comprises an extracellular domain comprising a variable region, a constant region, and a connecting peptide, a transmembrane domain, and an intracellular domain comprising a CD28 region and a CD3 ? ITAM region. Nucleic acids encoding the modified T cell receptors, and vectors comprising the nucleic acids are also disclosed. Additionally, a method for treating cancer and/or a viral infection is disclosed comprising administering a cell comprising the modified T cell receptor.
The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
An apparatus for dipping tablets into gelatin coating material and for spreading and setting the coating immediately after dipping is provided. Carrier plates having a plurality of tablet holders are transported from a tablet loading station to a dipping station along a transport guide.      At the dipping station, a carrier plate is mounted to a vacuum chamber. A set of vacuum tubes in the vacuum chamber are extended through the tablet holders to contact and lift the tablets off of the holders and secure the tablets to the tubes. In a preferred embodiment, the vacuum chamber is rotated 180° and a second carrier plate is mounted onto the housing and a second set of tubes secure the tablets to the plate. The carrier plates are alternately dipped and returned to the guide means where new plates with uncoated tablets replace the plates with coated tablets. Immediately after dipping the carrier plates enter a rotating station where the plate is rotated 360° and then replaced on the guide means for transportation to further processing stations. Preferably, the rotating station includes a similar vacuum chamber with vacuum tubes that are extended into the holder for securing the tablet during rotation.
BACKGROUND: Loneliness is a growing public health concern associated with substantial negative mental and physical health outcomes. Loneliness is especially relevant for individuals with a chronic illness, perhaps more so if their illness is rare. Little is known about the psychosocial experience of individuals with a rare chronic illness, and whether and how it may differ from the experience of individuals with common chronic illnesses. We compared the magnitude of loneliness in persons with a rare or common chronic illness and examined theoretically guided predictors of loneliness as follows: stigma, illness intrusiveness, social comparison, social support, support from healthcare providers, and self-efficacy.
METHOD: Individuals with a chronic illness (common or rare) completed an anonymous online survey (N = 952).
RESULTS: Individuals with common chronic illnesses were as lonely as those with a rare chronic illness. Loneliness in both groups was higher than that in population norms. Regression analyses reveal that independent of other predictors, loneliness was especially high among people who feel stigmatized by others, those who have less social support available, and people whose functioning is more disrupted by their illness (all p values < 0.01).
CONCLUSION: The similarity of loneliness in these groups reinforces the value of further systematic research to identify the needs of individuals with any type of chronic illness. Study findings highlight the importance of examining internalized stigma and social support as possible targets of intervention to reduce loneliness among individuals with a chronic illness, recognizing some of the unique features and challenges of their disorders, whether common or rare.
The type of treatment being studied has the advantages of wide applicability throughout the world (including developing countries) and low cost. An oral treatment is more accessible to patients than drugs given by injection or by inhalation.

Patients with confirmed PCP are randomized into one of three treatment groups. Group A receives SMX/TMP. Half of group A receives dapsone placebo (placebo is an inactive substance) daily plus trimethoprim placebo; the other half receives clindamycin placebo plus primaquine placebo. Group B is given dapsone plus trimethoprim. Half of group B receives SMX/TMP placebo; the other half receives clindamycin placebo plus primaquine placebo. Group C is given clindamycin plus primaquine. Half of group C receives SMX/TMP placebo, the other half receives dapsone placebo plus trimethoprim placebo. Treatment lasts 21 days; dosages will be adjusted for patients weighing less than 50 kg and more than 80 kg. Patients with a history of intolerance to SMX/TMP for whom rechallenge is considered medically contraindicated may be randomized to one of the non-sulfamethoxazole-containing arms.
The invention is based on the finding that the human RPT4 protein/gene can function as a therapeutic target for solid tumour type cancers, especially solid tumours of the colon, and that reducing the abundance of RPT4 in tumour cells causes a significant increase in cancer cell death, and potently decreases the survival and proliferation of cancer cells in tumour growth assays (FIGS.  3  and  4 ). A further, but linked, aspect of the invention is based on the finding that inhibitors of RPT4 significantly decrease the viability of chemotherapeutic-resistant tumours, especially solid tumours, especially colorectal solid tumours (FIG.  5 ). A further, but linked, aspect is based on the finding that the efficacy of conventional chemotherapeutic therapy, for example 5-FU/oxaliplatin therapy, is significantly improved when combined with treatment with a RPT4 inhibitor (FIG.  6 ). A further, but linked, aspect of the invention is based on the finding that levels of RPT4 in solid tumours such as colorectal cancer can function as a prognostic variable of outcome/survival (FIG.  2 ).
PURPOSE:To obtain the titled pharmaceutical preparation useful for skin diseases such as Behcet's disease, necrotic blood inflammation, etc., capable of being administered endermically without causing side effect, by forming a high polymer substance layer consisting of a high polymer substance pressure-sensitive at normal temperature and colchicine on a substrate. CONSTITUTION:An effective amount of colchicine is added to a high polymer substance pressure-sensitive at normal temperature, preferably (meth)acrylate high polymer substance [e.g., (meth)acrylic acid butyl ester, (meth)acrylic acid pentyl ester, etc.] in such a way that colchicine is dispersed uniformly or in high content at the surface layer part, and a high polymer substance layer is formed on a flexible substrate (e.g., cloth, plastic film, etc.), to give the titled pharmaceutical preparation. Colchicine administration is quantitatively carried out with a sufficient ODT effect, a partial concentration can be effectively raised, and diseases can be effectively remedied while lowering side effects. Colchicine is preferably adjusted to 1-500mug strength/cm<2>.